Director of the Board and advisor for clinical and regulatory programs.
Ulf’s past experience includes leading positions within oncology and clinical development at Celgene, Takeda, Pfizer and Eli Lilly.
He has played key roles in the clinical development and regulatory approval process of blockbusters Gemzar® (gemcitabine) and Evista® (raloxifene). Key contributions to the clinical development of pharmaceuticals such as Alimta® (pemetrexed), Revlimid® (lenalidomide) and Vidaza® (azacitidine) are also a part of Ulf’s track record.
In addition, he has led major Due Diligence processes which have resulted in multibillion dollar acquisitions, including Celgene’s acquisitions of Abraxis and Pharmion.View Profile
Senior Medical Advisor
Tore provides medical expertise in the development of clinical research programs. He has extensive experience of drug development focusing on clinical trials, safety and regulatory interactions.
He is an upper G.I. surgeon by training and was an external advisor to AstraZeneca from 1980 to 2000 where he was closely involved in the development of Losec® and Nexium®. He was also the principal investigator in numerous international clinical trials using acid suppressive therapy. He joined AstraZeneca full-time in 2000 as Global Medical Director.
Tore joined Isofol in mid-2014.View Profile
Dr. Nilsson, MD, PhD, is one of Scandinavia’s leading clinicians in urological oncology. He has served as a Professor of Oncology at the Karolinska Hospital, Stockholm, Sweden and has wide ranging clinical and research experience in the fields of oncology and nuclear medicine. In the industry, Prof. Nilsson has been part of the advisory boards of several leading pharmaceutical companies such as Bayer Healthcare, Janssen, Ipsen, Novartis, AstraZeneca, Pharmacia/Pfizer, Roche and Lilly. He is founder of Dextech Medical (Aktietorget, Stockholm) and is providing scientific and strategic advice as a member of the board of PledPharma (Nasdaq First North), and Spago Nanomedical (Aktietorget, Stockholm).View Profile
Dr. Alain Herrera, MD, PhD has contributed directly to the worldwide registration of, among others, the cytostatic oxaliplatin. Oxaliplatin in combination with fluorouracil and leucovorin constitute one of today’s basic regimens, FOLFOX, in treatment of colorectal cancer. Currently Dr. Herrera operates as a Senior Consultant within the field of Oncology. Prior to this Dr. Herrera held the position of Vice President of Global Oncology Business Strategy and Development at Sanofi and before that he was Head of Global Oncology Franchise at Sanofi. Dr. Herrera has also served as Chairman of Chiron Therapeutics Europe and as Managing Director of Pierre Fabre Oncology Laboratories. Dr. Herrera is part of the Supervisory Board of, among others; IDDI, Nanobiotix, PDCline Pharma, Gustave Roussy-Transfert and Arcad Foundation.View Profile